Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Golden Meditech Holdings. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
Golden Meditech Holdings's
is considered below, and whether this is a fair price.
Price based on past earnings
Golden Meditech Holdings's earnings available for a low price, and how does
this compare to other companies in the same industry?
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Golden Meditech Holdings has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
and how much profit it is expected to make.
Future estimates come from
professional analysts. Just like forecasting the weather, they don’t always get
Expected Healthcare industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Golden Meditech Holdings
expected to grow at an
Unable to compare Golden Meditech Holdings's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
Unable to compare Golden Meditech Holdings's earnings growth to the United States of America market average as no estimate data is available.
Unable to compare Golden Meditech Holdings's revenue growth to the United States of America market average as no estimate data is available.
Unable to determine if Golden Meditech Holdings is high growth as no earnings estimate data is available.
Unable to determine if Golden Meditech Holdings is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Golden Meditech Holdings's filings and announcements here.
Golden Meditech Holdings's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
Golden Meditech Holdings
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Golden Meditech Holdings's finances.
The net worth of a company is the difference between its assets and liabilities.
Golden Meditech Holdings is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Golden Meditech Holdings's cash and other short term assets cover its long term commitments.
This treemap shows a more detailed breakdown of
Golden Meditech Holdings's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
High level of physical assets or inventory.
Debt is covered by short term assets, assets are 4.5x debt.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
Mr. Yuen Kam is the Founder of Golden Meditech Holdings Limited (also known as, Golden Meditech Company Limited) and serves as Chairman, Chief Executive Officer and Compliance Officer. Mr. Kam is responsible for Golden Meditech Company Limited's overall strategic planning. He has more than 20 years of management experience in Business and International Trade. He was the Chairman of China Cord Blood Corporation since October 03, 2012 until January 31, 2018. He has been Executive Director of Golden Meditech Holdings Limited since April 1, 2015. He serves as a Director of Bio Garden Inc. Mr. Kam serves as a Director at Magnum Opus 3 International Holdings Limited. Mr. Kam graduated from Beijing Second Foreign Languages Institute, the PRC in 1985.
Yuen's compensation has been consistent with company performance over the past year.
Yuen's remuneration is lower than average for companies of similar size in United States of America.
Company Secretary & Executive Director
Investor Relations Manager
Zu Qin Lai
Chief Scientist of Qijieyuan and Inventor of TangHerb
Jian Zhong Jing
VP & Chief Representative of Shanghai Office
Dao Pei Lu
President of Shanghai Dao Pei Hospital
Bao Ping Shao
Chief Executive Officer of the Chinese Herbal Medicine Operation
Wei Zhong Ding
Chief Executive Officer of GM Medicare Management (China) Company Limited
Chief Executive Officer of Medical Devices Operation
Board of Directors Tenure
Average tenure and age of the
Golden Meditech Holdings
board of directors in years:
The tenure for the Golden Meditech Holdings board of directors is about average.
Board of Directors
Company Secretary & Executive Director
CFO & Executive Director of China Cord Blood Corporation
Golden Meditech Holdings Limited, an investment holding company, operates as an integrated healthcare company in the People’s Republic of China. It operates through five segments: Medical Devices, Hospital Business, Medical Insurance Administration, Chinese Herbal Medicines, and Cells and Tissues Storage and Genetic Testing Services. The Medical Devices segment develops, manufactures, and sells medical devices and accessories. This segment provides products that are specialized in blood recovery, purification, and treatment. The Hospital Business segment offers hospital management services; and operates hospitals in Beijing and Shanghai that provide obstetrics, gynecology, and pediatric medical services, as well as haematology treatments and healthcare services. The Medical Insurance Administration segment offers medical insurance administration services. This segment also provides operational and information technology solutions to medical insurance companies and healthcare institutions, as well as offers claims, review process, bill settlement, and data analysis services. The Chinese Herbal Medicine segment is involved in the research, development, manufacture, and sale of Chinese herbal medicines. The Cells and Tissues Storage and Genetic Testing Services segment engages in the provision of cells and tissues storage services, as well as related clinical applications. This segment also provides genetic testing and molecular pathology testing services. The company also engages in the software design business. The company was formerly known as Golden Meditech Company Limited and changed its name to Golden Meditech Holdings Limited in March 2010. Golden Meditech Holdings Limited was incorporated in 2001 and is headquartered in Beijing, the People’s Republic of China.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.